Showing results (21-30 of 40) with videos related to
Sort By:
Pageof 4
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Partnership between academia and industry for drug discovery in Alzheimer's diseaseAdrian J Ivinson, Roger Lane, Patrick C May, et al.Pharmacogenetics and Genomics|October 19, 2006
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's diseaseRafael Blesa, Roger Bullock, Yunsheng He, et al.International Journal of Geriatric Psychiatry|March 24, 2007
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsuleBengt Winblad, Jeffrey Cummings, Niels Andreasen, et al.Stroke|December 22, 2007
Neurological signs in relation to type of cerebrovascular disease in vascular dementiaSalka S Staekenborg, Wiesje M van der Flier, Elisabeth C W van Straaten, et al.International Journal of Geriatric Psychiatry|April 5, 2007
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's diseaseBengt Winblad, Ariane K Kawata, Kathleen M Beusterien, et al.Drug Safety|December 22, 2007
Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extensionWolfgang Oertel, Werner Poewe, Erik Wolters, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 8, 2009
Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel diseaseSalka S Staekenborg, Tanja Su, Elisabeth C W van Straaten, et al.Psychopharmacology|August 14, 2014
Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836Ming Zheng, Lieuwe Appel, Feng Luo, et al.Journal of Clinical Psychopharmacology|May 12, 2015
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind StudiesZubin Bhagwagar, Anne Torbeyns, Delphine Hennicken, et al.Pharmacogenetics and Genomics|March 13, 2008
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's diseaseRoger Lane, Howard H Feldman, Joanne Meyer, et al.Pageof 4